Chimeric spike mRNA vaccines protect against Sarbecovirus challenge in mice sciencemag.org - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from sciencemag.org Daily Mail and Mail on Sunday newspapers.
by Sarah Avery May 10, 2021 .
DURHAM – A potential new vaccine developed by members of the Duke Human Vaccine Institute has proven effective in protecting monkeys and mice from a variety of coronavirus infections – including SARS-CoV-2 as well as the original SARS-CoV-1 and related bat coronaviruses that could potentially cause the next pandemic.
The new vaccine, called a pan-coronavirus vaccine, triggers neutralizing antibodies via a nanoparticle. The nanoparticle is composed of the coronavirus part that allows it to bind to the body’s cell receptors, and is formulated with a chemical booster called an adjuvant. Success in primates is highly relevant to humans.
E-Mail
DURHAM, N.C. - A potential new vaccine developed by members of the Duke Human Vaccine Institute has proven effective in protecting monkeys and mice from a variety of coronavirus infections including SARS-CoV-2 as well as the original SARS-CoV-1 and related bat coronaviruses that could potentially cause the next pandemic.
The new vaccine, called a pan-coronavirus vaccine, triggers neutralizing antibodies via a nanoparticle. The nanoparticle is composed of the coronavirus part that allows it to bind to the body s cell receptors and is formulated with a chemical booster called an adjuvant. Success in primates is highly relevant to humans.
Antibody Persistence through 6 Months after the Second Dose of mRNA-1273 Vaccine for Covid-19 nejm.org - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from nejm.org Daily Mail and Mail on Sunday newspapers.
Date Time
Antiviral medication works against coronavirus in lab
CHAPEL HILL, N.C. – The number of new COVID-19 cases continues to rise in many parts of the world, with the highest incidence in the United States.
Although several highly effective vaccines have been authorized for emergency use, it may take considerable time to reach target vaccination levels needed for herd immunity due to the logistics of vaccine manufacturing, shipping, storage, and distribution as well as public acceptance.
Recently, SARS-CoV-2 variants have emerged which appear to have increased transmissibility and have added more challenges to ensure vaccine viability. Therefore, alternative treatments and preventive approaches that can be widely and rapidly implemented are urgently needed to curb the risk for COVID-19 related hospitalization and death in multiple settings including nursing homes and long-term care facilities.